Disruptive Technologies and Game-changing Companies in the Global Pharmaceutical Cell Banking Market

Proprietary CMO Cell Culture Technology Platforms are Disrupting the In-house-outsourced Balance of Cell Banking Services

USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This market insight on the global cell banking market analyses disruptive technologies and provides details on game-changing companies. Biopharmaceutical companies are increasingly partnering with CMOs and CROs to store their proprietary cell lines and develop new ones. With increased collaborations, CMOs are coming up with niche and specific services for cell line development and cell banking. They are focusing on providing gene to GMP services, thereby expanding their service portfolios. Mammalian cell culture technology is the highest-growing system across all other cell systems. With the increase in infectious diseases, the development of novel mammalian cell culture systems is expected to evolve. With the

Table of Contents

Disruptive Technologies and Game-changing Companies in the Global Pharmaceutical Cell Banking MarketExecutive SummaryKey FindingsMarket OverviewMarket Segment OverviewTransformation in the Industry EcosystemIndustry Value ChainGame-changing CompaniesCell Banking and Cell Line Development—Technology Trends8 Big Market Themes for Cell BankingTechnology Process Overview Technology Process Overview—Biopharmaceutical ProductionTechnology Process Overview—Timelines of the End-to-End Services Provided by Multiple CMOsTechnology Process Overview—Cell BankingTechnology Process Overview—Cell Banking (continued)Key Technology Trends Key Technology Trends—Cell BankingKey TechnologiesKey Technologies—Perfusion TechnologyKey Technologies—Single-use TechnologySingle-use/Disposable Manufacturing Technology versus Traditional Large Capacity Stainless Steel Bioreactors Key Technologies—Cryopreservation Reagents and Upstream & Downstream ProcessesKey Technology PlatformsHigh Growth in Mammalian Cell Culture TechnologyMammalian Cell Culture Technology PlatformsMammalian Cell Culture Technology Platforms (continued)Microbial Cell Culture TechnologyKey Companies to ActionKey Companies by RegionKey Companies by Region (continued)SGS Life SciencesSGS Life Sciences (continued)SGS Life Sciences (continued)Charles River LaboratoriesCharles River Laboratories (continued)Charles River Laboratories (continued)Wuxi AppTechWuxi AppTech (continued)Wuxi AppTech (continued)BioReliance CorporationBioReliance Corporation (continued)BioReliance Corporation (continued)Eurofins ScientificEurofins Scientific (continued)Eurofins Scientific (continued)LonzaLonza (continued)Lonza (continued)Key Mergers and Acquisitions and Partnerships and CollaborationsMerger, Acquisition, and Partnership AssessmentMerger, Acquisition, and Partnership Assessment (continued)Growth Opportunities4 Major Growth Opportunities The Last WordThe Last WordLegal DisclaimerThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition: Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.